3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
3
Stomach Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Malignant Solid Tumour
1
Intestinal Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
13
Cisplatin
10
pembrolizumab
7
Oxaliplatin
5
Leucovorin
5
Fluorouracil
5
durvalumab
4
Paclitaxel
4
Nivolumab
3
Injections
3
Immune Checkpoint Inhibitors
3
Capecitabine
3
camrelizumab
2
Docetaxel
2
Cetuximab
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
surufatinib
1
spartalizumab
1
silmitasertib
1
regorafenib
1
pertuzumab
1
manganese chloride
1
lenvatinib
1
irinotecan sucrosofate
1
folfirinox
1
devimistat
1
derazantinib
1
binimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Biliary Tract Neoplasms
×
Levoleucovorin
×
Clear all
NCT06428409
2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled